June Daffeh, MD
Internal Medicine · Kilmarnock, VANPI 1033120142
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,631 of the $4,189 with a category attached, or 86.7%. It is spread thinly across 34 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,202 and has fallen 55.2% since, to $539 in 2025. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$721
- Amgen$571
- Tosoh Bioscience, Inc.$558
- AbbVie$391
- Pfizer$270
- Lilly USA, LLC$238
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,63187%
- Gifts$55813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $721 |
| Amgen | 35 | $571 |
| Tosoh Bioscience, Inc. | 1 | $558 |
| AbbVie | 14 | $391 |
| Pfizer | 16 | $270 |
| Lilly USA, LLC | 17 | $238 |
| AstraZeneca | 12 | $166 |
| Silk Road Medical, Inc. | 1 | $158 |
| Daiichi Sankyo Inc. | 5 | $102 |
| Abbott | 4 | $94 |
| Scpharmaceuticals Inc. | 2 | $81 |
| Amarin Pharma, Inc. | 5 | $80 |
| Johnson & Johnson | 6 | $73 |
| Radius Health, Inc. | 2 | $67 |
| Neurocrine Biosciences, Inc. | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 4 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Astellas Pharma US Inc | 3 | $54 |
| GSK | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Mylan Specialty L.p. | 2 | $35 |
| Corcept Therapeutics | 1 | $34 |
| Merck | 1 | $31 |
| Almatica Pharma LLC | 1 | $27 |
| Exact Sciences | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Smith+Nephew | 1 | $19 |
| Viatris Specialty LLC | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,189 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 205 | $134,513 |
| OzempicSemaglutide | 32 | $44,560 |
| MounjaroTirzepatide | 29 | $37,011 |
| XareltoRivaroxaban | 18 | $32,513 |
| FarxigaDapagliflozin Propanediol | 17 | $23,881 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $11,619 |
| JardianceEmpagliflozin | 15 | $10,846 |
| GemtesaVibegron | 17 | $10,528 |
| LinzessLinaclotide | 12 | $6,563 |
| MyrbetriqMirabegron | 11 | $6,225 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,353 |
| BrilintaTicagrelor | 11 | $4,876 |
| Atorvastatin Calcium | 565 | $4,848 |
| PremarinEstrogens, Conjugated | 13 | $4,640 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 70 | $3,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $270 | $139,153218 claims |
| Novo NordiskOzempic | $721 | $44,56032 claims |
| Lilly USA, LLCMounjaro | $238 | $37,01129 claims |
| Johnson & JohnsonXarelto | $73 | $32,51318 claims |
| AstraZenecaFarxiga, Brilinta | $166 | $28,75728 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $15 | $10,52817 claims |
| AbbVieLinzess, Synthroid | $391 | $8,43159 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $6,22511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Kilmarnock
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Gautam GulatiMc Lean$136K
- Francesse BatailleDumfries$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.